Yoshi-hide Sato , Dousatsu Sakata , David Bolst , Edward C. Simpson , Andrew Chacon , Mitra Safavi-Naeini , Susanna Guatelli , Akihiro Haga
{"title":"Validation of Light–Ion Quantum Molecular Dynamics (LIQMD) model for hadron therapy","authors":"Yoshi-hide Sato , Dousatsu Sakata , David Bolst , Edward C. Simpson , Andrew Chacon , Mitra Safavi-Naeini , Susanna Guatelli , Akihiro Haga","doi":"10.1016/j.ejmp.2024.104850","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose:</h3><div>This study aims to validate the Light-Ion Quantum Molecular Dynamics (LIQMD) model, an advanced version of the QMD model for more accurate simulations in hadron therapy, incorporated into Geant4 (release 11.2).</div></div><div><h3>Methods:</h3><div>Two sets of experiments are employed. The first includes positron-emitter distributions along the beam path for 350 MeV/u <sup>12</sup>C ions incident on a PMMA target, obtained from in–vivo Positron Emission Tomography (PET) experiments at QST (Chiba, Japan). The second comprises cross-sections for 95 MeV/u <sup>12</sup>C ions incident on thin targets (H, C, O, Al, and Ti), obtained from experiments at GANIL (Caen, France). The LIQMD model’s performance is compared with the experimental data and the default QMD model results.</div></div><div><h3>Results:</h3><div>The LIQMD model can predict the profile shape of positron-emitting radionuclide yields with better accuracy than the default QMD model, although some discrepancies remains. The consistency observed in the production of positron-emitting radionuclides aligns with the thin target cross-section analysis. The LIQMD model significantly improves the differential and double-differential cross-sections of fragments produced in thin targets, especially in the forward direction. The overestimation of <sup>10</sup>C production in the in–vivo PET benchmark is consistent with the 95 MeV/u <sup>12</sup>C cross-section test. Overall, the LIQMD model demonstrates better agreement with experimental measurements for nearly all fragment species compared to the QMD model.</div></div><div><h3>Conclusions:</h3><div>The LIQMD model offers an improved description of the fragmentation process in hadron therapy. Future work should involve further validation against additional experimental measurements to confirm these findings.</div></div>","PeriodicalId":56092,"journal":{"name":"Physica Medica-European Journal of Medical Physics","volume":"128 ","pages":"Article 104850"},"PeriodicalIF":3.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physica Medica-European Journal of Medical Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1120179724011074","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose:
This study aims to validate the Light-Ion Quantum Molecular Dynamics (LIQMD) model, an advanced version of the QMD model for more accurate simulations in hadron therapy, incorporated into Geant4 (release 11.2).
Methods:
Two sets of experiments are employed. The first includes positron-emitter distributions along the beam path for 350 MeV/u 12C ions incident on a PMMA target, obtained from in–vivo Positron Emission Tomography (PET) experiments at QST (Chiba, Japan). The second comprises cross-sections for 95 MeV/u 12C ions incident on thin targets (H, C, O, Al, and Ti), obtained from experiments at GANIL (Caen, France). The LIQMD model’s performance is compared with the experimental data and the default QMD model results.
Results:
The LIQMD model can predict the profile shape of positron-emitting radionuclide yields with better accuracy than the default QMD model, although some discrepancies remains. The consistency observed in the production of positron-emitting radionuclides aligns with the thin target cross-section analysis. The LIQMD model significantly improves the differential and double-differential cross-sections of fragments produced in thin targets, especially in the forward direction. The overestimation of 10C production in the in–vivo PET benchmark is consistent with the 95 MeV/u 12C cross-section test. Overall, the LIQMD model demonstrates better agreement with experimental measurements for nearly all fragment species compared to the QMD model.
Conclusions:
The LIQMD model offers an improved description of the fragmentation process in hadron therapy. Future work should involve further validation against additional experimental measurements to confirm these findings.
期刊介绍:
Physica Medica, European Journal of Medical Physics, publishing with Elsevier from 2007, provides an international forum for research and reviews on the following main topics:
Medical Imaging
Radiation Therapy
Radiation Protection
Measuring Systems and Signal Processing
Education and training in Medical Physics
Professional issues in Medical Physics.